
Pharnext SA’s PXT3003 treatment for patients with Charcot-Marie-Tooth Disease (CMT) has shown positive interim results in its ongoing Phase III …

France-based clinical stage biopharma firm Pharnext has appointed Michel de Rosen to its board of directors. For nearly 25 years …
Femtosecond laser cuts lung tumour margin assessment time
Blood sensor detects Parkinson’s-associated proteins in 40 minutes
Ofichem acquires US drug substance CDMO Kinentia
Jager-van Dijk is new Arletta Pharma Solutions CEOÂ

